M51R VSV

M51R VSV is a genetically modified strain of **vesicular stomatitis virus (VSV)** characterized by a single amino acid substitution (methionine to arginine at position 51) in its matrix (M) protein[2][4]. This mutation severely reduces the virus’s ability to inhibit host interferon responses, resulting in robust induction of type I interferon (IFN) and related immune-stimulatory genes[2][4]. The attenuated phenotype of M51R VSV makes it safer and less virulent than wild-type VSV, and it is widely studied as a **vector for oncolytic virotherapy and as a vaccine platform**[1][3][4]. Its antitumor mechanism primarily involves selective infection and killing of tumor cells while eliciting potent antitumor immunity, particularly through engagement and activation of dendritic cells and CD8+ T cells[1][4]. The enhanced safety profile (reduced neurotoxicity, lower systemic dissemination) and immunogenicity have been exploited in both cancer and vaccine development (e.g., COVID-19 mucosal vaccines)[3][4].

Brand names

M51R VSVM-51R VSVM 51R VSV

Other names

VSV-M51RVSV-M-51RVSV-M 51RVSV ΔM51rVSV-M51RrVSV-M-51RrVSV-M 51R